Immatics NV (IMTX)

[FACT-MASTER]

IMTX: Clinical Trial Review:

1. NCT05958121 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05958121?spons=immatics&rank=3&tab=table

2. NCT05359445 IMA401 TCER® in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05359445?spons=immatics&rank=4&tab=table

3. NCT03686124 ACTengine® IMA203/?IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/?or Refractory Solid Tumors (ACTengine)
https://clinicaltrials.gov/study/NCT03686124?spons=immatics&rank=6&tab=table

Of interest is that all 3 have Data Monitoring Committees

https://www.ppd.com/wp-content/uploads/2020/07/decision-tree-graphic.pdf